This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
genetics: Archive
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
by Ekta Bagri
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
ILMNNegative Net Change BEAMNegative Net Change EDITNegative Net Change NTLANegative Net Change PRMENegative Net Change CRSPNegative Net Change
biotechnology biotechs gene-editing gene-therapy genetics genomics medical pharmaceuticals
3 Promising Genomics Stocks to Keep an Eye On in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
BEAMNegative Net Change NTLANegative Net Change KRYSPositive Net Change MGTXPositive Net Change
cell-therapy gene-therapy genetics genomics medical pharmaceuticals
3 Highly Ranked Medical Stocks to Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX,
by Shaun Pruitt
These highly ranked medical stocks have the value and essential services that investors may be looking for as tariff concerns and geopolitical tensions have started to rattle markets.
JAZZPositive Net Change PCRXPositive Net Change OPCHNegative Net Change
earnings genetics investing medical medical-devices pharmaceuticals
Bull of the Day: NVIDIA (NVDA)
by Kevin Cook
Owner of GPU architecture market accelerates "AI for everyone" with massive growth for years to come
NVDANegative Net Change CDNSNegative Net Change
artificial-intelligence gene-editing genetics genomics semiconductor smart-health software
Bear of the Day: Micron (MU)
by Kevin Cook
The "megalodon of memory" is vital to the AI revolution in mobile, autos, robotics, & medicine
MUNegative Net Change NVDANegative Net Change
artificial-intelligence automation autonomous-vehicles blockchain cloud-computing electric-vehicles genetics robotics semiconductor
2 Medical Stocks to Buy Before Earnings
by Shaun Pruitt
Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports.
CAHPositive Net Change LGNDNo Net Change
biotechnology earnings genetics medical pharmaceuticals
Time to Buy Cigna or Regeneron Stock Before Earnings?
by Shaun Pruitt
Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.
REGNNegative Net Change CIPositive Net Change
biotechnology earnings finance genetics insurance investing medical
BioPharma Giants Print Fresh All-Time Highs
by Bryan Hayes
The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.
REGNNegative Net Change BMYPositive Net Change
biotechnology cancer cell-therapy coronavirus earnings genetics hospitals immuno-therapy investing large-cap medical medical-devices pharmaceuticals
Bull of the Day: Pfizer Inc. (PFE)
by Bryan Hayes
With a dividend yield of 3% and a top Zacks VGM score of 'A', it's not hard to see why PFE is a top stock pick.
PFEPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus dividend-investing dividends earnings genetics hospitals immuno-therapy investing large-cap medical oncology-screening pharmaceuticals vaccines
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
REGNNegative Net Change GILDPositive Net Change CDMOPositive Net Change
biotechnology biotechs cancer cell-therapy coronavirus earnings gene-therapy genetics hospitals immuno-therapy investing medical oncology-screening pharmaceuticals smart-health vaccines